Pharmaguy's Insights Into Drug Industry News
185.9K views | +1 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Fish Oil Claims Not Supported by Research

Fish Oil Claims Not Supported by Research | Pharmaguy's Insights Into Drug Industry News | Scoop.it
The vast majority of clinical trials have found no evidence that fish oil supplements lower the risk of heart attack and stroke.


From 2005 to 2012, at least two dozen rigorous studies of fish oil were published in leading medical journals, most of which looked at whether fish oil could prevent cardiovascular events in high-risk populations. These were people who had a history of heart disease or strong risk factors for it, like high cholesterol, hypertension or Type 2 diabetes.


All but two of these studies found that compared with a placebo, fish oil showed no benefit.


And yet during this time, sales of fish oil more than doubled, not just in the United States but worldwide, said Andrew Grey, an associate professor of medicine at the University of Auckland in New Zealand and the author of a 2014 study on fish oil in JAMA Internal Medicine.


“There’s a major disconnect,” Dr. Grey said. “The sales are going up despite the progressive accumulation of trials that show no effect.”

Pharma Guy's insight:


The pharmaceutical industry is often criticized for developing new Rx drugs having little value over current medications. Such drugs are called "me-too" drugs because of their similarity to existing Rx drugs. Glaxo has now taken this to a completely NEW level: developing an Rx drug that is a "me-too" of existing over-the-counter dietary supplements. I am talking about LOVAZA, aka omega-3-acid esters approved by the FDA for the treatment of high triglycerides.

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Omega3 drugs Recruit Pawn Stars & Fish for DTC Campaigns

Omega3 drugs Recruit Pawn Stars & Fish for DTC Campaigns | Pharmaguy's Insights Into Drug Industry News | Scoop.it
Celebrity endorsement, copay cards and online edutainment are some of the ways marketers are dueling for attention in the prescription omega3 space.


Amarin is poised to announce a celebrity tie-in with cable-TV star Rick Harrison (host of the showPawn Stars) as part of an integrated campaign to boost awareness of its one-year-old Vascepa brand. And AstraZeneca, whose prescription omega-3 drug Epanova is a relative newcomer, recently launched an unbranded, digital edutainment effort. 


Amarin's partnership with Harrison, who was diagnosed with the condition, works the correlation between knowing trig-treatment facts and not being hoodwinked in his own pawn shop.


“If I hadn't checked with my doctor, I would have made the mistake many make, thinking dietary supplement omega-3s are actually over-the-counter drugs,” Harrison says in a video on the related site LowerMyTrigs.com, adding that Pawn Stars teaches that “knowing what's valuable and authentic is important to success.” 


Meanwhile, in a campaign that takes its cue from the aquatic theme of DTC advertising done by GlaxoSmithKline's Lovaza—but also departs from it—AZ posted three videos as part of an unbranded consumer effort called “Take it From a Fish.” The videos, dubbed “Love,” “Diet” and “Tri,” take the viewer into the seafood section of the grocery store as two talking fish carry on a casual conversation about healthy eating habits.


Pharma Guy's insight:


Doesn't Harrison often ask his dad about "what's valuable and authentic" on the Pawn Stars show?


As far as I am concerned, these Rx drugs are "me-too" versions of existing over-the-counter dietary supplements, no  matter what Harrison might say about Vascepa


Read my take on the comments made by Harrison: 

Did Pawn Star Rick Harrison Ask His Daddy About the Value of Vascepa Omega-3 Fish Oil?
more...
No comment yet.